Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer

Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer. Irinotecan's active metabolite is inactivated by UDP-glucuronosyltransferase 1A1 (UGT1A1), which is deficient in Gilbert's syndrome. Irinotecan and metabolites are transported by P-glycoprotein, encoded by...

詳細記述

保存先:
書誌詳細
主要な著者: Glimelius, B, Garmo, H, Berglund, Å, Fredriksson, L A, Berglund, M, Kohnke, H, Byström, P, Sørbye, H, Wadelius, M
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2011
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3036798/
https://ncbi.nlm.nih.gov/pubmed/20177420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2010.10
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料